Two important catalysts highlighted at JPM$NKTR214 longawaited lung cancer data not until ESMO$CLVS bladder cancer initial data likely at ESMO too potentially registrational and first PARPi to mkt in bladderESMO19 is shaping up to be a big mtg f

Two important catalysts highlighted at JPM $NKTR-214 long-awaited lung cancer data not until ESMO $CLVS bladder cancer initial data likely at ESMO too, potentially registrational and first PARPi to mkt in bladder #ESMO19 is shaping up to be a big mtg f

Two important catalysts highlighted at JPM $NKTR-214 long-awaited lung cancer data not until ESMO $CLVS bladder cancer initial data likely at ESMO too, potentially registrational and first PARPi to mkt in bladder #ESMO19 is shaping up to be a big mtg for biotech again this yr!

More From BioPortfolio on "Two important catalysts highlighted at JPM $NKTR-214 long-awaited lung cancer data not until ESMO $CLVS bladder cancer initial data likely at ESMO too, potentially registrational and first PARPi to mkt in bladder #ESMO19 is shaping up to be a big mtg f"